首页 | 本学科首页   官方微博 | 高级检索  
     

密集膀胱灌注对抑制非肌层浸润性膀胱肿瘤术后复发的随机对照研究
引用本文:谷宝军,冯超,谢弘,司捷旻,刘章顺,宋鲁杰,刘莺,张心如. 密集膀胱灌注对抑制非肌层浸润性膀胱肿瘤术后复发的随机对照研究[J]. 临床泌尿外科杂志, 2011, 26(4): 249-253,257. DOI: 10.3969/j.issn.1001-1420.2011.04.004
作者姓名:谷宝军  冯超  谢弘  司捷旻  刘章顺  宋鲁杰  刘莺  张心如
作者单位:上海交通大学附属第六人民医院泌尿外科,上海,200233
摘    要:目的:观察短期密集疗程膀胱腔内蒽环类药物灌注化疗对抑制非肌层浸润性膀胱肿瘤(nonmuscle invasive bladder cancer,NMIBC)经尿道电切术(TUR)后复发的效果。方法:我院自2006年1月~2008年12月对221例NMIBC患者行TUR术,经随机分为两组,密集疗程组术后执行表柔比星(epirubicin,EPI)40mg/40ml每周1次,连续8次的腔内灌注方案;常规化疗组则在连续8次的密集灌注化疗后续行40mg/40ml每月1次,连续10次的灌注方案。记录患者每3个月1次膀胱镜检查情况至术后24个月或肿瘤复发。结果:共有141例获得完整资料。24个月随访期中;45例(31.9%)肿瘤复发。其中常规化疗组22例(30.1%),密集化疗组23例(33.2Vo)(p-0.64)。复发时间常规化疗组为(8.73±5.23)个月,密集化疗组为(8.74±4.42)个月(P=0.38)。15例(10.6%)复发肿瘤进展,其中常规化疗组7例(9.6%),密集疗程组8例(11.8%)(P=0.675)。对141例患者的肿瘤大小,单发多发,初发复发,肿瘤病理类型,以及临床分期方面进行分层研究,密集疗程组与常规化疗组的无肿瘤复发率差异均无统计学意义。结论:TUR术后短期密集葸环类药物膀胱腔内灌注化疗可以获得与常规灌注化疗方案相同的降低NMIBC复发的效果。

关 键 词:膀胱肿瘤  非肌层浸润性  腔内化疗  经尿道电切  肿瘤复发  蒽环类抗肿瘤药物

Compact Intravesical Instillations of Anthracyclines as Prophylaxis for Recurrence after Transurethral Resection of Non-Muscle-Invasive Bladder Cancer: a Prospective, Randomized Controlled Study
Baojun GU,Chao FENG,Hong XIE,Jieming SI,Zhangshun LIU,Lujie SONG,Ying LIU,Xinru ZHANG. Compact Intravesical Instillations of Anthracyclines as Prophylaxis for Recurrence after Transurethral Resection of Non-Muscle-Invasive Bladder Cancer: a Prospective, Randomized Controlled Study[J]. Journal of Clinical Urology, 2011, 26(4): 249-253,257. DOI: 10.3969/j.issn.1001-1420.2011.04.004
Authors:Baojun GU  Chao FENG  Hong XIE  Jieming SI  Zhangshun LIU  Lujie SONG  Ying LIU  Xinru ZHANG
Affiliation:1Department of Urology, Shanghai Jiaotong University affiliated Shanghai Sixth People's Hospital, Shanghai, 200233, China)
Abstract:Objective:To evaluate the effect of compact anthracyclines intravesical chemotherapy as prophylaxis for recurrence after transurethral resection (TUR) of non muscle invasive bladder cancer (NMIBC). Methods: From 2006.1 to 2008.12,221 NMIBC patients underwent TUR in our hospital. Patients were randomized into'two groups. Group A patients were treated with intravesical instillation of epirubicin (EPI) 40 mg/ 40 ml saline every week for 8 weeks. Group B patients were continuously administrated with same dose EPI every month for 10 months after the same schedule as group A was finished. The results of every 3 months regular cystoscopy exam were recorded. The follow up were ended when tumor recurred or no tumor recurrence was reported 24 months after TUR. Resuits:141 patients completed their documents. 45 cases (31.9/%) was found tumor recurrence,23 and 22 patients were found in each group, respectively. No statistical difference was found between two groups (P= 0.64). The recurrence time of both groups was (8.73±5.23) mo and (8.74±4.42) mo,respectively. 8 patients (11.8%) were found tumor progressed in Group A while 7 patients (9.6%) were found in Group B (P=0.675). Further stratified statistical analysis showed that there was no difference in free tumor recurrence rate between two groups, whatever in the aspect of the tumor size, solitary tumor or not, first occurred or recurred patients, the path-ologic findings and clinical staging in each group was compared. Conclusions:Compact anthracyclines intravesical instillation after TUR has the same recurrence prevention effectiveness as the regular intravesical schedule. The monthly intravesical instillation followed compact schedule seems unnecessary for recurrence prophylaxis.
Keywords:bladder tumor  no muscle invasive  intravesical chemotherapy  transurethral resection  tumor recurrence  anthracyclines
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号